Overview

Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This study was conducted in Africa, Europe, the Middle-East and South America. The primary objective of this registry was to observe the use of single dose and multi-dose use of activated recombinant human factor VII and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Factor VIII